Furazolidone - CAS 67-45-8
Catalog number: 67-45-8
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C8H7N5O3
Molecular Weight:
225.16
COA:
Inquire
Targets:
Antibacterial
Description:
Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity, binds bacterial DNA, which leads to the gradual inhibition of monoamine oxidase used to treat anorexia and antagonism of thiamin utilization in poultry (IC50=12.7 μM).
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
Yellow Solid
Synonyms:
3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone;3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; Topazone;Trifurox
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Antimicrobial.
Quality Standard:
Enterprise Standard/EP
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Melting Point:
247-249°C
InChIKey:
PLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI:
1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
Canonical SMILES:
C1COC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-]
1.Formulation and advantages of furazolidone in liposomal drug delivery systems.
Alam MI1, Paget T1, Elkordy AA2. Eur J Pharm Sci. 2016 Mar 10;84:139-45. doi: 10.1016/j.ejps.2016.01.017. Epub 2016 Jan 18.
Furazolidone has proven to have antiprotozoal and antibacterial activity. A number of literature supported its use against Helicobacter pylori. This potential application opens new prospects of its use in clinical settings in triple therapy. In order to avoid side effects associated with this drug, liposomal mucoadhesive drug delivery that can work locally in stomach is considered as an appropriate approach. This study is a focus on formulations and in vitro characterization of liposomes containing furazolidone. Therefore, the effects of variable amounts of drug and cholesterol on encapsulation efficacy and in vitro drug release were evaluated for different liposomal formulations. Mucoadhesive behavior of chitosan coated liposomal at two different pHs was also evaluated and increase in pH from 1.3 to 4.5 increased mucoadhesion from 42% to 60% respectively. Increasing the amount of drug from 4mg to 5mg increased encapsulation activity however, increasing the drug any further decreased encapsulation activity.
2.Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure.
Fakheri H1, Bakhshi Z2, Bari Z3, Alhooei S3. Middle East J Dig Dis. 2016 Jan;8(1):51-6. doi: 10.15171/mejdd.2016.07.
BACKGROUND Several large clinical trials and meta-analyses have shown about 20% failure to eradicate Helicobacter pylori (H.pylori), necessitating investigations for second-line treatments. The aim of this study was to evaluate the effects of clarithromycin-containing quadruple regimen after nitroimidazole-containing quadruple therapy failure. METHODS Thirty two patients who had failed 10-day H.pylori treatment with omeprazole, amoxicillin, bismuth subcitrate, and metronidazole (OABM) regimen and 31 patients who had failed 10-day treatment with omeprazole, amoxicillin, bismuth subcitrate, and furazolidone (OAMF) regimen entered the study. They all received omeprazole (20 mg), amoxicillin (1 gr), bismuth subcitrate (240 mg) and clarithromycin (500 mg) twice a day for 10 days. Eight weeks after treatment, H. pylori eradication was assessed by (14)C-urea breath test. RESULTS Totally 61 patients completed the study. According to intention to treat (ITT) analysis, eradication rates by second-line OABC regimen were 84.
3.Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.
Zhang F1, Bao ZJ1, Shi DM1, Xiang P1, Xiao L1, Huang YQ1, Zhang GS1, Yin SM1. Braz J Med Biol Res. 2016 Feb;49(2):e5080. doi: 10.1590/1414-431X20155080. Epub 2016 Feb 5.
We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple therapy plus postural change after dosing for Helicobacter pylori eradication in gastrectomized patients. We compared 76 gastric stump patients with H. pylori infection (GS group) with 50 non-gastrectomized H. pylori-positive patients who met the treatment indication (controls). The GS group was divided into GS group 1 and GS group 2. All groups were administered bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days. GS group 1 maintained a left lateral horizontal position for 30 min after dosing. H. pylori was detected using rapid urease testing and histologic examination of gastric mucosa before and 3 months after therapy. Mucosal histologic manifestations were evaluated using visual analog scales of the updated Sydney System. GS group 1 had a higher prevalence of eradication than the GS group 2 (intention-to-treat [ITT]: P=0.
4.[Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province].
Meng X1, Liu GF, Wu J, Kong CC, Zhao LW, Zhu XY, Ji CG, Yang L. Zhonghua Yi Xue Za Zhi. 2016 Jan 26;96(4):270-2. doi: 10.3760/cma.j.issn.0376-2491.2016.04.008.
OBJECTIVE: To evaluate the resistance of Helicobacter pylori (H.pylori) clinical isolates to various antibiotics, in order to guide rational drug use in Hebei Province.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products


CAS 144-82-1 Sulfamethizole

Sulfamethizole
(CAS: 144-82-1)

Sulfamethizole is a sulfathiazole antibacterial agent.

CAS 59695-59-9 Cephalexin hydrochloride

Cephalexin hydrochloride
(CAS: 59695-59-9)

Cefalexin hydrochloride is a cephalosporin antibiotic. It is a first-generation cephalosporin antibiotic introduced in 1967 by Eli Lilly and Company. It is an o...

CAS 122841-10-5 Cefoselis

Cefoselis
(CAS: 122841-10-5)

Cefoselis, a new parenteral cephalosporin, was active against clinical isolates of both gram-positive and gram-negative aerobic bacteria. The activity of Cefose...

CAS 144-74-1 Sulfathiazole sodium

Sulfathiazole sodium
(CAS: 144-74-1)

Sulfathiazole is a short-acting sulfa drug. It was a common oral and topical antibiotic until less toxic alternatives were discovered. It is no longer used in h...

CAS 56238-63-2 Cefuroxime Sodium

Cefuroxime Sodium
(CAS: 56238-63-2)

Cefuroxime sodium is a second-generation cephalosporin antibiotic resistant to beta-lactamase.

CAS 245342-14-7 LED209

LED209
(CAS: 245342-14-7)

LED209 is a highly selective for histidine sensor kinase QseC that blocks both norepinephrine- and epinephrine-triggered QseC-dependent virulence gene expressio...

CAS 15176-29-1 Edoxudine

Edoxudine
(CAS: 15176-29-1)

Edoxudine, synthesised via organopalladium intermediates, is an antiviral drug.

CAS 6004-24-6 Hexadecylpyridinium chloride monohydrate

Hexadecylpyridinium chloride monohydrate
(CAS: 6004-24-6)

Hexadecylpyridinium chloride monohydrate is a broad antimicrobial spectrum with a rapid bactericidal effect on gram-positive pathogens and a fungicide effect on...

CAS 118081-34-8 Ceftibuten dihydrate

Ceftibuten dihydrate
(CAS: 118081-34-8)

Dihydrate form of Ceftibuten which is one of the third-generation cephalosporin antibiotics.

CAS 1672-88-4 Furagin

Furagin
(CAS: 1672-88-4)

Furagin (a nitrofurantoin analog) has the same efficacy in treating acute cystitis as Ciprofloxacin, however the duration of therapy is longer. Antibacterial.

FR-193879
(CAS: 194928-82-0)

FR-193879, a cephem derivative, is an efficacious anti-Helicobacter pylori cephalosporin.

CAS 3116-76-5 Dicloxacillin

Dicloxacillin
(CAS: 3116-76-5)

Dicloxacillin, a β-lactamase resistant penicillin similar to oxacillin, used to treat infections caused by susceptible (non-resistant) Gram-positive bacteria.

CAS 115550-35-1 Marbofloxacin

Marbofloxacin
(CAS: 115550-35-1)

Marbofloxacin exhibits high bactericidal activity against a broad spectrum of aerobic Gram-negative and some Gram-positive bacteria, as well as Mycoplasma spp.

CAS 5490-27-7 Dihydrostreptomycin sesquisulfate

Dihydrostreptomycin sesquisulfate
(CAS: 5490-27-7)

Dihydrostreptomycin sesquisulfate is a derivative of Streptomycin used to treat bacterial diseases in cattle, pigs and sheep.

LY 173013
(CAS: 126165-78-4)

LY173013 is an antibacterial agent with bicyclic pyrazolidinones containing a novel aza-γ-lactam ring structure. The properties of this compound appear to be re...

CAS 957-68-6 7-Aminocephalosporanic acid

7-Aminocephalosporanic acid
(CAS: 957-68-6)

7-Aminocephalosporanic acid is a potent inhibitor of bacterial (S. aureus) β-lactamase.

CAS 1264-72-8 Colistin Sulfate

Colistin Sulfate
(CAS: 1264-72-8)

Colistin is a cyclic cationic decapeptide linked to a fatty acid side chain, it belongs to a group of similarly structured bacterial antimicrobial peptides.

CAS 61336-70-7 Amoxicillin trihydrate

Amoxicillin trihydrate
(CAS: 61336-70-7)

Amoxicillin is a moderate-spectrum, bacteriolytic, β-lactam antibiotic in the aminopenicillin family used to treat bacterial infections caused by susceptible Gr...

CAS 122-16-7 Sulfanitran

Sulfanitran
(CAS: 122-16-7)

Sulfanitran, a sulfonamide derivative, could be commonly used as an anticoccidial drug for animals.

CAS 502487-67-4 SQ109

SQ109
(CAS: 502487-67-4)

SQ109 is a novel antitubercular drug. It was screened out from a big chemical library designed around the active pharmacophore of ethambutol (EMB). SQ109 displa...

Chemical Structure

CAS 67-45-8 Furazolidone

Quick Inquiry

Verification code

Featured Items